Atsiliepimai
Aprašymas
Neurodegenerative diseases are unique in that they result in progressive neuronal loss, complicated molecular pathologies, and few disease-modifying treatment approaches. The traditional treatment methods are usually compromised by low bioavailability, systemic toxicity, and the daunting challenges of blood-brain barrier. The book is a multi-disciplinary and comprehensive exploration on how nanoscale technologies are changing the understanding, diagnosis, and treatment of neurodegenerative diseases. Nanotechnology in Neurodegenerative Disease clarifies the mechanism bases of nanomaterial-neural interactions, in which nanoparticles have the ability to regulate protein aggregation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and impaired proteostasis, which are among the prominent pathological hallmarks common in neurodegenerative diseases. It critically evaluates the new nanotechnological delivery systems based on nanotechnology in targeted drug delivery, gene and RNA therapeutic applications, neurotrophic factor-delivery models and controls, and targeted release systems aimed at improving the precision of therapeutic applications and reducing off-target effects. Also, the book discusses the use of nanotechnology in the discovery of biomarkers, the development of state-of-the-art neuroimaging, and the discovery of diseases at an earlier stage with a strong focus on translational solutions connecting findings made at the bench to clinical use.
Neurodegenerative diseases are unique in that they result in progressive neuronal loss, complicated molecular pathologies, and few disease-modifying treatment approaches. The traditional treatment methods are usually compromised by low bioavailability, systemic toxicity, and the daunting challenges of blood-brain barrier. The book is a multi-disciplinary and comprehensive exploration on how nanoscale technologies are changing the understanding, diagnosis, and treatment of neurodegenerative diseases. Nanotechnology in Neurodegenerative Disease clarifies the mechanism bases of nanomaterial-neural interactions, in which nanoparticles have the ability to regulate protein aggregation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and impaired proteostasis, which are among the prominent pathological hallmarks common in neurodegenerative diseases. It critically evaluates the new nanotechnological delivery systems based on nanotechnology in targeted drug delivery, gene and RNA therapeutic applications, neurotrophic factor-delivery models and controls, and targeted release systems aimed at improving the precision of therapeutic applications and reducing off-target effects. Also, the book discusses the use of nanotechnology in the discovery of biomarkers, the development of state-of-the-art neuroimaging, and the discovery of diseases at an earlier stage with a strong focus on translational solutions connecting findings made at the bench to clinical use.
Atsiliepimai